Skip Navigation



NDT Advance Access published online on January 5, 2008
Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfm848
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
23/5/1600    most recent
gfm848v3
gfm848v2
gfm848v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Ortiz, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ortiz, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2008]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org


Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy

Alberto Ortiz1, João P. Oliveira2, Steven Waldek3, David G. Warnock4, Bruno Cianciaruso5, Christoph Wanner6 and on behalf of the Fabry Registry

1 Nephrology, Fundacion Jimenez Diaz, Madrid, Spain 2 Nephrology and Genetics, Hospital São João, Porto, Portugal 3 Adult Inherited Metabolic Diseases, Hope Hospital, Salford, UK 4 Medicine, University of Alabama at Birmingham, Birmingham, AL, USA 5 Division of Nephrology, University "Federico II" of Naples, Italy 6 Division of Nephrology, University of Würzburg, University Hospital, Würzburg, Germany

Correspondence and offprint requests to: Alberto Ortiz, Unidad de Diálisis, Fundación Jiménez Díaz, Av Reyes Católicos 2, 28040 Madrid, Spain. Tel: +34-91-5504940; Fax: +34-91-544-2636; E-mail: aortiz{at}fjd.es



  Abstract

Background. Fabry disease, an X-linked genetic disorder with deficient {alpha}-galactosidase A activity, is characterized by kidney disease and kidney failure. The spectrum of kidney disease has not been well defined, especially in female patients.

Methods. We did a cross-sectional retrospective analysis of natural history of glomerular filtration rate (estimated— eGFR), albuminuria and proteinuria in 1262 adult patients (585 males, 677 females) from the Fabry Registry.

Results. Twenty-eight percent of males (age 20–79 years) and 13% of females (age 20–82 years) had chronic kidney disease (CKD) with eGFR < 60 ml/min/1.73 m2. Overt proteinuria (>300 mg/24 h) was demonstrated in 43 and 26% of males and females with CKD stage 1, respectively, and the proportions were higher with more severe kidney involvement. However, 11% of males and 28% of females with eGFR < 60 ml/min/1.73 m2 had proteinuria <300 mg/ 24 h. Of eGFR ≥ 60 ml/min/1.73 m2 patients without overt proteinuria (n = 93), 55% of the males and 35% of the females had albuminuria >30 mg/24 h. Systemic blood pressure was ≥130/80 mmHg in 48% and 67% of patients with eGFR ≥ and <60 ml/min/1.73 m2, respectively, with no significant differences between males and females. Proteinuria values were significantly correlated with systolic blood pressure in both sexes.

Conclusions. Kidney involvement in Fabry disease is more prevalent and heterogeneous than previously reported. Proteinuria is an early complication, but may not be overt in patients with advanced kidney disease. This analysis, which includes more females than males, confirms that a significant proportion of females suffer moderate to severe kidney involvement in Fabry disease.

Keywords: blood pressure; Fabry disease; nephropathy; proteinuria; registry

Received for publication: 13. 6.07
Accepted in revised form: 2.11.07


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
A. Ortiz, B. Cianciaruso, M. Cizmarik, D. P. Germain, R. Mignani, J. P. Oliveira, J. Villalobos, B. Vujkovac, S. Waldek, C. Wanner, et al.
End-stage renal disease in patients with Fabry disease: natural history data from the Fabry Registry
Nephrol. Dial. Transplant., October 21, 2009; (2009) gfp554v1.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
A. B. Fogo, L. Bostad, E. Svarstad, W. J. Cook, S. Moll, F. Barbey, L. Geldenhuys, M. West, D. Ferluga, B. Vujkovac, et al.
Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN)
Nephrol. Dial. Transplant., October 15, 2009; (2009) gfp528v1.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
R. Schiffmann, D. G. Warnock, M. Banikazemi, J. Bultas, G. E. Linthorst, S. Packman, S. A. Sorensen, W. R. Wilcox, and R. J. Desnick
Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy
Nephrol. Dial. Transplant., July 1, 2009; 24(7): 2102 - 2111.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
B. Oqvist, B. M. Brenner, J. P. Oliveira, A. Ortiz, R. Schaefer, E. Svarstad, C. Wanner, K. Zhang, and D. G. Warnock
Nephropathy in Fabry disease: the importance of early diagnosis and testing in high-risk populations
Nephrol. Dial. Transplant., June 1, 2009; 24(6): 1736 - 1743.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.